Presseinformationen weltweit an Journalisten und Leser verbreiten
CHF 16.0 million cash & cash equivalents, trade and other receivables as at June 30, 2020 Revenues increased to CHF 1.3 million driven by strong MagnetOs sales, up 42% versus H1 2019 Net operating costs of CHF 7.5 million led Mehr
. Grant of European patent entitled ‘Osteoinductive composites’ Notice of allowance of Japanese patent from the same patent family Further strengthens Kuros’s position as a leader in the field of orthobiologics Kuros Biosciences (SIX: KURN) today announced that its Dutch Mehr
Kuros Biosciences (SIX:KURN) today announced that its Annual General Meeting approved all resolutions proposed by the Board of Directors.Two proposed resolutions relating to capital increases were not put up for voting. The Annual General Meeting approved the Annual Report, the Mehr
. Financial highlights CHF 21.9 million cash & cash equivalents, trade and other receivables as at December 31, 2019 Revenues increased to CHF 2.6 million Net operating costs decreased to CHF 13.5 million Operational highlights U.S. & European product sales Mehr
Grant of US patent covering the use of PTH containing matrices for spinal fusion Grant of US patent covering osteoinductive materials made by certain methods Further strengthens Kuros’s position as a leader in the field of orthobiologics Kuros Biosciences (SIX: Mehr